Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC
Recruiting now · Phase 2
Conditions studied: Locally Advanced Vulvar Carcinoma, Squamous Cell Carcinoma of the Vulva
In brief
A phase 2 randomised controlled trial will be performed in which the efficacy and safety of standard treatment (primary chemoradiation; consisting of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for six weeks) and experimental treatment (NACT; consisting of carboplatin and paclitaxel in a 3-weekly scheme) will be compared in 98 patients with LAVC, registered from eight national medical centres.
Key facts
- Study ID
- NCT05905315
- Run by
- The Netherlands Cancer Institute
- People needed
- 98
- Starts
- 2024-01-01
- Expected to finish
- 2029-09-01
- Last updated by the study team
- 2024-04-15
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Woman ≥ 18 years
- Signed and written informed consent.
- Histologically-confirmed primary or recurrent squamous cell carcinoma vulvar cancer FIGO stage Ib - IVa, T1b or higher, any N, M0.
- Local tumour through which the size or localization implies requirement of treatment through primary chemoradiation or surgery consisting of extensive surgery (meaning surgery damaging pelvic organs or exenterative surgery). This can imply;
- T1b or larger tumour with (irresectable) groin metastases
- T1b or larger tumour with a close relationship to and/or involvement of the urethra or anal sphincter
- World Health Organization performance status of 0-2
- Adequate haematological function defined by platelet count >100x10E9/L, absolute leukocyte >3X10E9/L or neutrophil count (ANC) >1.5x10E9/L, and hemoglobin >6.0 mmol/L
- Adequate hepatic function defined by a total bilirubin level ≤1.5x the upper limit of normal (ULN) range and ASAT and ALAT levels ≤2.5x ULN for all subjects
- Adequate renal function defined by an estimated creatinine clearance ≥50mL/min according to the Cockroft-Gault formula (or local institutional standard method)
- Beta HCG level of 14 mIU/mL or below for women of childbearing potential
- Highly effective contraception for patients if the risk of conception exists
You may not qualify if…
- Patients with highly suspicious or positive metastases to the pelvic lymph nodes
- Patients eligible for radical local excision without involvement of other organs
- Any psychiatric condition that would prohibit the understanding or rendering of informed consent
- Prior radiotherapy to the pelvis or groin area limiting full dose chemoradiation according to protocol
- Existing neuropathy which will hinder the intake of chemotherapy
Where it is running
- NKI-AVL — Amsterdam, Netherlands (enrolling)
- LUMC — Leiden, Netherlands (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.